With a continually growing patient population and no approved treatments, NASH presents a huge unmet clinical need. Drug developers are racing to bring an effective therapeutic to market as
quickly as possible. However, developing a robust market entry strategy for Europe is not without its challenges. Join your peers and industry leading experts at this workshop to learn how to navigate the European drug development landscape.
Attend this expert led workshop to:
Workshop Leader: George O’Rourke, Managing Director, GO Biotech Consulting
The molecular mechanisms triggering NASH in the liver are unknown. Currently, there is a lack of industry consensus on the mechanisms driving NASH disease and therefore which are the most appropriate to target therapeutically.
Furthermore, replicating human NASH disease in vivo is one of the most challenging aspects of preclinical drug development. Currently there are a plethora of animal models available, however, no mice model completely fulfils the clinical features observed in humans.
This workshop will review the latest advances in understanding the molecular mechanisms driving NASH disease. We will review commonly used animal models of NAFLD/NASH referring to their advantages and disadvantages. You will leave this workshop with a comprehensive understanding of potential mechanisms driving NASH and which mouse models are most appropriate for your NASH candidate.
Join this workshop to:
Workshop Leader: Ronit Shiri-Sverdlov, Professor, Hepatic Inflammation and Metabolic Health, Maastricht University